Company’s antibody profiling technology could shed new light on the complex role of the immune system and inflammation in aging.
US biotech Infinity Bio has closed an $8 million Series A financing round to support the expansion of its immune system intelligence platform. The company is developing scalable, high-quality antibody profiling technology designed to enhance understanding of inflammation, immunity and disease mechanisms – including age-related diseases.
Founded in 2023 and headquartered in Baltimore, Infinity Bio focuses on deciphering the immune system’s role in health and disease through comprehensive antibody profiling. The company’s proprietary MIPSA (Molecular Indexing of Proteins by Self Assembly) technology enables a detailed analysis of the antibody “reactome” – the full spectrum of antibodies present in an individual’s immune system.
Developed at Johns Hopkins University in the Laboratory of Precision Immunology, MIPSA integrates principles from genomics, proteomics and bioinformatics to deliver high-resolution insights into immune responses. Infinity Bio’s core technology allows researchers to examine how antibodies interact with thousands of antigen targets simultaneously, all in a single assay. These capabilities support wide-ranging applications, including biomarker discovery, therapeutic development, vaccine design and the optimization of monoclonal antibodies – with significant potential in longevity biotech applications.
“There is an emerging and prominent appreciation that aberrant inflammatory processes contribute to accelerated organ aging and reduction of overall healthspan,” Infinity’s scientific founder, Ben Larman, an associate professor of pathology at Johns Hopkins University, told us. “To better understand the nature of these immune responses, we must identify their molecular targets, which include chronic infections, environmental irritants, components of the microbiome, and autoimmune reactions.”
Infinity Bio claims its technology provides this needed clarity by screening antibodies against vast panels of antibody targets to establish each individual’s antibody reactome.
“We expect major advances in the field will develop as adoption and interest in the antibody reactome grows among immunologists, epidemiologists and biotech companies,” Larman told us.
With its newly secured funding, Infinity Bio plans to broaden its commercial operations and scale its technology to meet growing demand from academic institutions, government agencies and the biopharmaceutical sector. Its 9,000-square-foot facility is already capable of processing thousands of samples per week, supporting both research and clinical development.
In conjunction with the raise, Infinity Bio has also bolstered its market position by acquiring the assets of immune profiling company Serimmune for an undisclosed amount. The acquisition of a company with a complementary focus is expected to fuel the launch of new services in the latter half of 2025.
Interestingly, the financing round was led by Illumina Ventures, the investment arm of genomics giant Illumina, which yesterday demonstrated its commitment to multiomics with its acquisition of SomaLogic. Could the ‘reactome’ be next on the company’s omics shopping list?
“We applaud the scientific prowess of Infinity Bio to provide insights into the immune system through its antibody reactome profiling platform,” said Illumina Ventures’ Dr Malek Faham. “Combined with the assets from Serimmune, this enhanced, more comprehensive technology is a game changer for biomedical researchers who can use it for a broad range of applications to accelerate their discoveries.”
The funding round also included participation from PTX Capital, Blackbird BioVentures and Propel Baltimore Fund. The funding is intended to accelerate platform innovation, drive commercial growth and spur the development of new service offerings.
